Observational Study “Cladribine”

Observed Drugs

Title of the Observational Study

AWB : EMR700568-012
Langfristige Daten zur Arzneimittelsicherheit von oral verabreichtem Cladribine bei MS-Patienten zu erhalten, indem Häufigkeit und Risikofaktoren für best. Ereignisse über einen längeren Zeitraum an Probanden untersucht wird, die zuvor an klinischen Versuchen mit oral verabreichtem Cladribine teilgenommen haben.

Registered on
03/18/2010
Start date
04/01/2010
End date
12/31/2018
Executing company
Outcome Europe Sarl (CRO)
Sponsor
Merck Serono SA-Geneva
Number of Docs1
n/a
Number of Patients2
2000
Payment per Patient3
7280.00 €
Fee details
für einen Zeitraum von 8 Jahren ,pro Patient

Background

Independent journalism needs independent funding

Others can write stories. We want to reveal. We are the first investigative newsroom in Germany, which is independent, ad-free, and non-profit.

For us, the core of journalism means uncovering injustice and shortcomings in society. That’s why we investigate corruption in the health system, politicians abusing their power, and an elite that believes that rules are for the others.

To do our job, we need people, who support us. We ask you, too, to become a member and enable the work of 16 investigative journalists at CORRECTIV.

We are convinced that without independent and critical media, democracy fought for and won by our ancestors, cannot survive for long.